First AD

Second AD

IgAN vs Other Glomerular Diseases

Can you explain the immune system dysregulation that leads to IgA nephropathy? How does this differ from other glomerular diseases?

Videos

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Advancing IgAN Care: Exploring the Next Wave of Treatments

IgA nephropathy is characterized by immune system dysregulation, primarily involving aberrant glycosylation of IgA1 molecules. This leads to the formation of immune complexes that deposit in the glomerular mesangium, triggering inflammation and glomerular injury. Unlike other glomerular diseases, IgA nephropathy is specifically associated with IgA1, whereas other conditions may involve different immunoglobulins or immune mechanisms. The pathogenesis of IgA nephropathy is distinct due to its unique involvement of mucosal immune responses and genetic predispositions, setting it apart from other glomerulopathies that may have more systemic or varied immune triggers.

Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.

Overview of IgAN and Its Common Symptoms

IgAN Progression

Biomarkers for IgAN

Genetic Screening for IgAN

Impact of IgAN on Quality of Life

Misdiagnosis and Barriers to Early Detection of IgAN

Differential Diagnoses of IgAN

Significance of Proteinuria for Potential IgAN

Proteinuria Variability and IgAN Diagnosis

Biomarkers and Improving IgAN Diagnostic Accuracy

Primary Treatment Goals for Patients With IgAN

Proteinuria Reduction in Long-Term Kidney Damage Prevention

Symptoms Management and Targeting the Root Cause of IgAN